2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL
SOURCE: BridgeBio Pharma, Inc.; The New England Journal of Medicine – In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained…
SOURCE Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight…
09.17.2024 at 7:30 AM EDT – Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial…
SOURCE – Tyra Biosciences, Inc. – In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein– -TYRA remains on track to submit ACH Investigational…
SOURCE: Bridge Bio, Inc. QED Therapeutics, an affiliate company of BridgeBio, is an Emerald Sponsor of this year’s Achondroplasia & Skeletal Dysplasia Research Conference, June 28-30 in Baltimore, Maryland. This…
This weekend, BioMarin, the Diamond Sponsor for the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, presented new data at the Pediatric Endocrine Society Meeting in Chicago. BioMarin announced positive…
